Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...2223242526272829303132...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report. (Pubmed Central) -  Dec 21, 2022   
    A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients...This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy. (Pubmed Central) -  Dec 17, 2022   
    Then the patient received the sixth line of treatment, camrelizumab/lorlatinib, for 9 antitumor cycles, resulting in PR...To our knowledge, this is the first documented case of cCR in a patient with ALK-positive advanced lung adenocarcinoma treated with multiple lines of therapy followed by surgical treatment. This case reveals the possible survival benefit of immunotherapy after multiple line treatment in ALK-positive advanced lung adenocarcinoma, indicating that it is possible find new therapeutic targets based on NGS molecular detection and provide precise therapeutic strategies for clinical practice when drug resistance or progression occurs in cancer therapy.
  • ||||||||||  Kineret (anakinra) / SOBI
    Single Institution Review of Anakinra for the Management of Icans in CAR T-Cell Therapy (World Center Marriott Cypress Foyer Alcove 1/ Cypress Foyer Alcove 2; In-Person) -  Dec 15, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_881;    
    In our pt cohort, pts with delayed onset of ICANS often were steroid refractory, necessitating the use of Anakinra. It is unclear whether the use of Anakinra impacted the duration of ICANS but was not associated with an increased risk of infection.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis. (On Demand | Level 1, West Hall; Poster Board No. D1) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_728;    
    Chemotherapy-free treatments may be an option for these patients beyond the first-line setting. While regorafenib is typically used in third or later lines, these real-world data suggest it is often a preferred option following triplet+bev treatment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. C7) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_716;    
    We included mCRC patients with RAS/BRAF wild-type tumors receiving EGFR mAb (cetuximab or panitumumab) in 1st line (1L, n = 248) or in 2L+ of therapy (n = 2,118). RAS/RAF WT mCRC patients with baseline alterations in RTK genes have less favorable outcomes on EGFR inhibitors (intrinsic resistance), and post-EGFR mAb samples (acquired resistance) converge around RTK and MAPK alterations, particularly MET, in real-world data.
  • ||||||||||  Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer. (On Demand | Level 1, West Hall; Poster Board No. A11) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_680;    
    In this comparative effectiveness study of a cohort of Medicare recipients and the Bronx population, with mCRC, biochemotherapy was associated with an improvement in OS, especially in the 1st year. Patients receiving biochemotherapy are more likely to receive further lines of chemotherapy upon disease progression.